Today, the melanoma research landscape has never been more dynamic. In the last decade alone, 15 new therapeutic options have earned FDA approval and more than 500 clinical trials are actively enrolling patients with melanoma. Patients are living longer, better lives as a result.
The downside? It's never been harder for patients, advocates, and doctors alike to keep up. This talk, presented by Dana Farber Cancer Institute's Dr. Elizabeth Buchbinder, overviews emerging melanoma therapies and exciting clinical trials.
